Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (currently amended) A method for purifying viruses from a first solution, the method comprising:

   (a) combining the first solution with an anionic polyelectrolyte and a cationic polyelectrolyte, wherein the cationic polyelectrolyte and ~~the~~ anionic polyelectrolyte can ~~bind~~ form complexes with viruses, to form a ~~section~~ second solution; ~~and~~

   (b) allowing complexes of the viruses, anionic polyelectrolyte, and cationic polyelectrolyte to form in the second solution, and

   [[(b)]] (c) centrifuging the second solution to obtain a supernatant and a pellet, wherein the pellet comprises the ~~virus~~ viruses.

2. (previously presented) The method of claim 1, wherein the anionic polyelectrolyte is selected from the group consisting of glycosaminoglycans and polysaccharides.

3. (previously presented) The method of claim 2, wherein the glycosaminoglycans and polysaccharides are sulfated.

4. (previously presented) The method of claim 1, wherein the anionic polyelectrolyte is selected from the group consisting of chondroitin sulfates, heparin, heparan sulfate, keratan sulfate, carrageenans, fucoidan, poly-L-glutamic acid, poly-L-aspartic acid, poly(glycolic acid), poly(lactic acid), and poly(lactic-co-glycolic acid).

5. (previously presented) The method of claim 4, wherein the anionic polyelectrolyte is chondroitin sulfate C.

6. (previously presented) The method of claim 1, wherein the cationic polyelectrolyte is a cationic polymer that complexes with the anionic polyelectrolyte.

7. (previously presented) The method of claim 1, wherein the cationic polyelectrolyte is selected from the group consisting of (diethylamino)ethyl dextran, histones, protamine, poly-L-arginine, poly-L-histidine, and poly-L-lysine.

8. (previously presented) The method of claim 1, wherein the cationic polyelectrolyte is hexadimethrine bromide.

9. (previously presented) The method of claim 1, wherein the first solution further comprises proteoglycans.

10. (previously presented) The method of claim 1, further comprising separating the pellet from the supernatant, and then resuspending the pellet in a resuspension buffer.

11. (previously presented) The method of claim 10, wherein the volume of the resuspension buffer is no greater than one-tenth the volume of the solution, thereby resulting in at least a ten-fold concentration of the virus.

12. (previously presented) The method of claim 10, wherein the volume of the resuspension buffer is no greater than one-hundredth the volume of the solution, thereby resulting in at least a one-hundred-fold concentration of the virus.

13. (previously presented) The method of claim 10, wherein the resuspension buffer comprises phosphate-buffered saline.

14. (previously presented) The method of claim 10, wherein the resuspension buffer comprises cell culture medium.

15. (previously presented) The method of claim 10, wherein the resuspension buffer comprises a pharmaceutically acceptable carrier.

16. (previously presented) The method of claim 1, wherein the virus is a retrovirus.

17. (previously presented) The method of claim 1, wherein the virus is an enveloped virus.

18. (previously presented) The method of claim 1, wherein the virus is selected from the group consisting of human immunodeficiency virus, lentiviruses, Moloney murine leukemia virus, herpes simplex virus, Epstein-Barr virus, human cytomegalovirus, influenza viruses, poxviruses, and alphaviruses.

19. (previously presented) The method of claim 1, wherein the anionic polyelectrolyte is added before the cationic polyelectrolyte.

20. (previously presented) The method of claim 1, wherein the anionic polyelectrolyte and the cationic polyelectrolyte are added simultaneously.

21. – 33. (Cancelled)

34. (previously presented) The method of claim 1, wherein the anionic polyelectrolyte comprises chondroitin sulfate C and the cationic polyelectrolyte comprises hexadimethrine bromide.

35. (previously presented) The method of claim 1, wherein the anionic polyelectrolyte comprises iota carrageenan and the cationic polyelectrolyte comprises DEAE dextran.

36. (previously presented) The method of claim 1, wherein the anionic polyelectrolyte comprises poly-L-glutamate and the cationic polyelectrolyte comprises poly-L-lysine.

37. (previously presented) The method of claim 1, wherein the anionic polyelectrolyte comprises heparan sulfate and the cationic polyelectrolyte comprises protamine.

38. (previously presented) The method of claim 1, further comprising dissociating the virus from the polyelectrolytes.

39. (previously presented) The method of claim 1, wherein the cationic polyelectrolyte is added before the anionic polyelectrolyte.

40. (new) The method of claim 1, further comprising separating the pellet from the supernatant.